Scancell - SCIB1 patent granted

Tuesday, Oct 25 2011 by

Scancell, the Nottingham based cancer vaccine developer, announced that a European composition of matter patent has been granted for SCIB1, the company's lead vaccine. SCIB1 is being developed for the treatment of melanoma and is currently in phase I clinical trials.

The SCLP share price has decreased by 41% over the last year.

Scancell Holdings Plc is currently graded c by LCF Research. To learn more, follow the link.


Disclaimer:  

This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.


Do you like this Post?
Yes
No
0 thumbs up
0 thumbs down
Share this post with friends



Scancell Holdings PLC is a United Kingdom-based pharmaceutical company. The Company’s principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms. The Company’s cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase II clinical trials. SCIB1 is a plasmid Deoxyribonucleic Acid (DNA), which encodes a human antibody molecule engineered to express a melanoma antigen called Tyrosinase-Related Protein 2 (TRP2) plus two helper T cell epitopes. The product pipeline of the Company consists of SCIB2, which stimulates immune responses to the lung cancer antigen NY-ESO-1. more »

Share Price (AIM)
29.33p
Change
10.7%
Mkt Cap (£m)
59.6
P/E (fwd)
n/a
Yield (fwd)
n/a



  Is Scancell Holdings fundamentally strong or weak? Find out More »


What's your view on this thread? Log In to Comment Now

You can track all @StockoChat comments via Twitter




Stock Picking Tutorial Centre



Stock Picking Simplified

Stockopedia takes your stock picking to the next level with cutting edge Stock Reports & Screening tools.


Get started
or Take a Tour to find out more.
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder